GLP-2 (rat) CAS NO.195262-56-7
TECHNICAL SPECIFICATIONS
| Item | Specification |
|---|---|
| Product Name | GLP-2 (rat) |
| CAS NO. | 95262-56-7 |
| Appearance | White to off-white lyophilized powder |
| Molecular Formula | C166H256N44O56S |
| Molecular Weight | 3796.22g/mol |
| Purity (RP-HPLC) | ≥95% |
| Solubility | ≥1 mg/mL in water; ≥138.05 mg/mL in DMSO; soluble in aqueous/DMSO mixed system |
| Endotoxin | ≤1.0 EU/mg |
| Biological Activity | Intestinal epithelium-specific growth factor; stimulates intestinal cell proliferation and inhibits apoptosis |
| Storage Conditions | Store desiccated at ≤-20°C in dark, dry condition under nitrogen. |
| Stock Location | Stock in USA |
| MOQ | 1g |
1.MECHANISM OF ACTION
Rat GLP-2 exerts its biological effects by binding and activating the specific GLP-2 Receptor (GLP-2R), a G-protein coupled receptor (GPCR) belonging to the glucagon receptor family. The GLP-2R is predominantly expressed on enteroendocrine cells, subepithelial myofibroblasts, and enteric neurons within the gastrointestinal tract, but not on enterocytes themselves. Receptor activation primarily signals through the Gs protein, leading to adenylate cyclase stimulation and increased intracellular cyclic AMP (cAMP).
- Rodent Intestinal Injury & Repair Models: Investigating the therapeutic potential of GLP-2 in experimental models of colitis, intestinal ischemia-reperfusion injury, chemotherapy/radiation-induced mucositis, and small bowel resection (short bowel syndrome).
- Gut Mucosal Biology: Studying the mechanisms of crypt cell proliferation, villus growth, and epithelial cell survival in normal and diseased states.
- Nutrient Absorption Research: Evaluating the effects of GLP-2 on the expression and function of intestinal nutrient transporters (e.g., for glucose, peptides).
- GLP-2 Receptor (GLP-2R) Pharmacology: Using rat-derived cells or tissues to characterize receptor binding, signaling, and the effects of specific agonists/antagonists.
2.PRODUCT INDICATIONS
- Preclinical Proof-of-Concept: Extensive research using rat (and human) GLP-2 in animal models demonstrated its potent efficacy in promoting intestinal mucosal growth, reducing injury, and improving function after massive small bowel resection, chemotherapy, or inflammatory damage.
- Foundation for Human Therapy: The promising preclinical data with native GLP-2 led to the development of a long-acting, DPP-IV-resistant analog: Teduglutide (Gattex®/Revestive®).
- Approved Clinical Drug: Teduglutide is an FDA and EMA-approved drug for the treatment of Short Bowel Syndrome (SBS) in adults and children. It reduces dependence on parenteral nutrition by enhancing intestinal absorption and adaptation, directly translating the biological actions of GLP-2 observed in rat models to human patients.
3.CLINICAL EFFICACY OF PRODUCT
4.DELIVERY & SHIPPING
We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods
Main Method: International Air Freight
We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.
